Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional patients continues in BIRCH BIOX-101 Phase IIb ICH study preparations ongoing, to start upon close of Series B 12 February 2025 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has raised €2.7 millio

UK’s first not-for-profit Focused Research Organisation supported by Department for Science, Research and Innovation’s Research Ventures Catalyst programme and matched industry, philanthropic & charitable support raising a total of £25.8 million Goal to turn disordered proteins into viable drug targets via AI-enhanced experimental and computational tools & comprehensive datasets of disordered protein-drug interactions 11 February 2025 – Bind Research was today launched as the UK’s first not-for

Feb. 11, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to share that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer (CRC) screening test. Starting this January, patients across Germany can access this new version of the Company’s screening test, in time for Colorectal Cancer Awareness Month in March. First introduce

FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis RMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority Review Enrollment in NEXICART-2 study accelerating; next update planned for H1 2025 Feb. 10, 2025 -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMM

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients Maintenance of BCVA and reduction of CST in these previously treated patients Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections Feb. 10, 2025 -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of n

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and Drug Administrati

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications for marketing authorization. CORDStrom, developed by INmune Bio is a patent pending, off the shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases that has significant clinical develo

Feb. 10, 2025 -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01

Feb. 10, 2025 -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, provided the funding to support ENA’s clinical development of INNA-051. A simple to administer, virus-agnostic, sea

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disea